Medtide Inc. Announces Completion of H Share Full Circulation

Key Points Investors Must Know

• Full Circulation of H Shares Completed: Medtide Inc. has successfully completed the conversion of 68,201,112 unlisted shares into H shares, effective March 9, 2026.
• Commencement of Trading: The newly converted H shares will begin trading on the Hong Kong Stock Exchange at 9:00 a.m. on March 10, 2026.
• Shareholding Structure Changed: Following the conversion, all of the Company’s shares will be H shares, increasing the free float and potentially enhancing liquidity for investors.
• Regulatory Milestones Achieved: The conversion follows the application for H share full circulation, the issuance of the Filing Notice from the China Securities Regulatory Commission (CSRC), and the official regulatory approvals.

Detailed Analysis and Potential Impact for Shareholders

Medtide Inc. (Stock Code: 3880), a joint stock company incorporated in China and listed in Hong Kong, has announced a major milestone for its equity structure. As of March 9, 2026, the Company has completed the conversion of 68,201,112 unlisted shares into H shares. The listing of these converted shares will begin at 9:00 a.m. on March 10, 2026, marking the full circulation of H shares for the Company.

This event is highly significant for the following reasons:

1. Enhanced Liquidity: With all shares now classified as H shares and listed on the Hong Kong Stock Exchange, the total number of H shares increases from 73,598,888 (51.90% of total issued shares) to 141,800,000 (100% of total issued shares). This effectively transforms the entire share capital of the Company into a freely tradable form, which is expected to significantly improve market liquidity and trading volumes.
2. Potential Impact on Share Price: The greater free float and liquidity could attract new institutional and retail investors, potentially supporting the share price. However, the increase in tradable shares could also create initial selling pressure as previously unlisted shareholders may choose to monetize their holdings.
3. Regulatory Compliance and Transparency: The conversion follows a structured regulatory process, including approval from the CSRC, providing shareholders with confidence regarding compliance and governance standards.

Shareholding Structure Before and After Conversion

Board Statement and Cautionary Note

The Company’s Board, led by Chairwoman and CEO Dr. Xu Qi, has advised shareholders and potential investors to exercise caution when dealing in the Company’s H shares. This is a standard warning in periods of significant change, as price volatility may be expected following the listing of a large volume of previously unlisted shares.

The Company’s Board comprises experienced executive, non-executive, and independent non-executive Directors, further reinforcing the governance structure.

Conclusion

The completion of H share full circulation is a major development for Medtide Inc., with direct implications for liquidity, investor access, and potential share price movement. Shareholders should stay alert to market reactions in the coming days as the new shares commence trading.

Disclaimer: This article is prepared for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisors before making investment decisions. The author and publisher do not accept any liability for losses that may arise from reliance on this information.

View MEDTIDE Historical chart here